Metanoia Press · In preparation
N,N-Dimethyltryptamine is the strangest member of the classic family. Vaporized, it acts within seconds and is gone in minutes, yet people describe those minutes as among the most vivid experiences of their lives. It is also, remarkably, a molecule the human body appears to make in trace amounts, and one that occurs across an enormous range of plants. Our forthcoming book gives DMT the same whole-system treatment we gave the mushroom: the chemistry, the brain, the tradition, and the honest edges.
What the Book Will Cover
A simple tryptamine built from tryptophan, why it's inactive by mouth alone, and how the ayahuasca brew solves that problem.
A potent agonist at the 5-HT2A serotonin receptor, the same doorway shared by psilocybin and LSD, and what "breakthrough" states reveal about perception.
From Amazonian snuffs to the visionary lineage, and the enduring puzzle of a psychedelic the body itself seems to produce.
Intravenous and inhaled DMT now in early trials for depression, the science of a very short-acting medicine.
DMT works, like most of the family, primarily through the brain's 5-HT2A serotonin receptor. Taken by mouth on its own it does almost nothing: the enzyme monoamine oxidase in the gut breaks it down before it can act. That single pharmacological fact is the hinge of the whole story: combine DMT with a MAO-inhibiting plant and it becomes orally active, which is exactly what the Amazonian ayahuasca brew does.
Its clinical chapter is just opening. An intravenous DMT candidate reported a rapid antidepressant signal in an early-phase trial, published in a leading medical journal: promising, small, and early. As always, we hold the promise and the uncertainty together.
Reliability: the receptor pharmacology is well established (strong). The clinical evidence is early-stage and preliminary. Full sources will accompany the finished book.